Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

NCT07022483 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

710

Enrollment

INDUSTRY

Sponsor class

Conditions

Endometrial Cancer

Interventions

DRUG: Trastuzumab Deruxtecan
DRUG: Chemotherapy

Sponsor

Daiichi Sankyo

Collaborators

[object Object]